JOHN HOPE FRANKLIN CENTER
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1838-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.duke.edu
Coping Skills Training for Early Rheumatoid Arthritis
Not Applicable
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Behavioral: Comprehensive Coping Skills TrainingBehavioral: Arthritis Education SessionsBehavioral: Standard Care
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Duke University
- Target Recruit Count
- 105
- Registration Number
- NCT00056394
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Weight Loss Maintenance (WLM)
Not Applicable
Completed
- Conditions
- Cardiovascular DiseasesHeart DiseasesObesityDiabetes Mellitus, Non-insulin DependentHypertension
- Interventions
- Behavioral: Personal contact (PC)Behavioral: Interactive technology (IT)
- First Posted Date
- 2003-02-14
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1685
- Registration Number
- NCT00054925
Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer
Not Applicable
Completed
- Conditions
- Breast CancerDepressionMalnutritionProstate CancerFatiguePsychosocial Effects of Cancer and Its Treatment
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Duke University
- Registration Number
- NCT00037024
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Intrathecal Busulfan in Treating Patients With Recurrent, Refractory, or Metastatic Leptomeningeal Tumors
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT00003462
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Phase 1
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 36
- Registration Number
- NCT00002986
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00016991
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors
Phase 2
Completed
- Conditions
- Brain and Central Nervous System TumorsNeuroblastoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005955
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
Phase 1
Completed
- Conditions
- Brain and Central Nervous System TumorsChildhood Germ Cell TumorHead and Neck CancerKidney CancerNeuroblastomaOvarian CancerSarcomaTesticular Germ Cell Tumor
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT00005952
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide in Treating Patients With Brain Metastases
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Registration Number
- NCT00005954
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Phase 1
Completed
- Conditions
- NeuroblastomaBrain and Central Nervous System TumorsMetastatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Duke University
- Registration Number
- NCT00003461
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath